"investigational"@en . " "@en . "N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide"@en . "Sufentanilo"@en . . . "Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability."@en . " "@en . . . "LD₅₀: 18.7 mg/kg (IV in mice)"@en . "approved"@en . "Sufentanil"@en . . . . . . . "Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain."@en . "Humans and other mammals"@en . . "Jacob Mathew, J. Killgore, \"New methods for the synthesis of alfentanil, sufentanil, and remifentanil.\" U.S. Patent US20060149071, issued July 06, 2006."@en . . . . . . . . . . "An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]"@en . . . . . . . . . . . . . . . . "265 minutes"@en . "Sufentanyl"@en . . . . . . . . . . . . . . . "N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide"@en . . . . . . . . . "56030-54-7"@en . . . . . . . "Sufentanil"@en . . "Sufentanilum"@en . .